Updates in Cerebral Venous Thrombosis

Curr Cardiol Rep. 2022 Jan;24(1):43-50. doi: 10.1007/s11886-021-01622-z. Epub 2022 Jan 13.

Abstract

Purpose of review: Cerebral venous thrombosis (CVT) is a rare cause of stroke that most commonly affects younger women. Here, we review new literature relevant to the management and prognosis of individuals with CVT and ongoing areas of uncertainty.

Recent findings: Direct-acting oral anticoagulants (DOACs) are being increasingly integrated into routine care but are not yet recommended by guidelines. Recent randomized clinical trials and available case series offer reassuring safety data. Routine use of endovascular therapy is not associated with improved outcomes. The relationship between recanalization and prognosis is uncertain. The evidence base for management of CVT continues to improve. Ongoing areas of uncertainty include duration of therapy and whether certain subgroups of patients may benefit from neurointervention or personalized approaches to antithrombotic strategy. The state of knowledge will continue to benefit from large collaborative international efforts, and integration of patient partnerships to identify research priorities.

Keywords: Anticoagulation; Cerebral venous thrombosis; DOAC; Endovascular therapy; Prognosis; Recanalization.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Factor Xa Inhibitors / therapeutic use
  • Female
  • Humans
  • Intracranial Thrombosis* / drug therapy
  • Stroke* / drug therapy
  • Venous Thrombosis* / drug therapy

Substances

  • Anticoagulants
  • Factor Xa Inhibitors